A platform approach to creating novel therapeutic solutions
ProstaNOva Therapeutics develops differentiated therapeutic candidates through a proprietary platform built on prostaglandin biology, nitric-oxide donor functionality, and translational scientific design.
The platform is built around biologically active compounds derived from natural regulators and nitric-oxide donor chemistry. As reflected in supporting materials, this approach encompasses prostaglandin-related structures and a scalable compound design aimed at improving pharmacological properties and broadening therapeutic relevance.
Pilot program: critical limb ischemia
Critical limb ischemia represents the initial pilot development focus and the first practical translational pathway for the platform. It is presented as the lead program — not as the full extent of the platform's potential.
Beyond CLI, the platform has the potential to support additional therapeutic development directions.
Alongside CLI, supporting materials also reference ophthalmology and respiratory programs, reinforcing the company's positioning as a scalable, multi-indication platform.
Critical Limb Ischemia
Ophthalmology
Respiratory Programs
Additional indications may be considered as the platform advances.
The company is presented as a developer of platform-based assets through selective partnerships and the advancement of individual programs across indications.
Internal legal mechanics, ownership structure, and legacy IP arrangements are not disclosed on the public website.